New Dosing Recommendations for Intuniv with Concomitant CYP3A4 Modulators

Intuniv is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets
Intuniv is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets

The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding concomitant use of strong and moderate CYP3A4 inhibitors or inducers.

The updated labeling now includes a table of recommended dosage adjustments for patients taking concomitant CYP3A4 inhibitors or inducers.  

Related Articles

  • For patients starting Intuniv while currently on a CYP3A4 modulator, the Intuniv dose should be decreased by half if taking strong or moderate CYP3A4 inhibitors, or possibly doubled if taking strong or moderate CYP3A4 inducers.
  • For patients continuing Intuniv while adding a CYP3A4 inhibitor, the Intuniv dose should be decreased by half if taking a strong or moderate CYP3A4 inhibitor, or possibly doubled over 1–2 weeks if taking strong or moderate CYP3A4 inducers. 
  • For patients continuing Intuniv while stopping a CYP3A4 modulator, the Intuniv dose should be increased to the recommended level if taking strong or moderate CYP3A4 inhibitors, or decreased over 1–2 weeks if taking strong or moderate CYP3A4 inducers.

Intuniv, a central alpha2A-adrenergic receptor agonist, is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulants. It is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets. 

For more information call (800) 828-2088 or visit Intuniv.com.

Loading links....